Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07324551 · ClinicalTrials.gov registry record
Microfabricated Microcatheter Advantages in Middle Meningeal Artery Embolization: an Early Experience at a Single Center
A clinical trial of Chronic Subdural Hematoma and Hemorrhage Brain, sponsored by Ohio State University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07324551 is a study of Chronic Subdural Hematoma and Hemorrhage Brain that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 100 participants, below the 1,417-participant average among 4 other Chronic Subdural Hematoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07324551, a study of Chronic Subdural Hematoma and Hemorrhage Brain, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the function of matched pair Aristotle 14 Guidewire and Plato Microcatheter in MMA embolization treatment for chronic subdural hematoma compared to surgeon's preference
Conditions Studied
Interventions
- DEVICE Matched pair Aristotle 14 guidewire and Plato 17 microcatheter
- DEVICE Surgeon combination preference
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2029-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07324551
The ClinicalTrials.gov registry entry for NCT07324551 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,417-participant average among 4 other Chronic Subdural Hematoma trials with a reported enrollment target (93% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Subdural Hematoma appearing as the primary indexed condition, and to 2 interventions - of which Matched pair Aristotle 14 guidewire and Plato 17 microcatheter is the first listed.
NCT07324551 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07324551 about?
NCT07324551 is a clinical study titled "Microfabricated Microcatheter Advantages in Middle Meningeal Artery Embolization: an Early Experience at a Single Center". The purpose of this study is to evaluate the function of matched pair Aristotle 14 Guidewire and Plato Microcatheter in MMA embolization treatment for chronic subdural hematoma compared to surgeon's preference
What is the current status of trial NCT07324551?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-11-03. Estimated completion is 2029-07-01.
What conditions does trial NCT07324551 study?
This clinical trial studies the following conditions: Chronic Subdural Hematoma, Hemorrhage Brain.
What interventions are being tested in trial NCT07324551?
The interventions under investigation include: Matched pair Aristotle 14 guidewire and Plato 17 microcatheter (DEVICE), Surgeon combination preference (DEVICE).
Who is sponsoring clinical trial NCT07324551?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07324551 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Subdural Hematoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)
RECRUITING
-
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
RECRUITING · NA
-
Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection
RECRUITING · Phase 1
-
Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.